Prospective study on early virologic response to treatment with interferon α-2b plus ribavirin in patients with chronic hepatitis C genotype 1b

Hepatology Research

Volumn 33, Issue 4, 2005, Pages 285-291

  Nagaki, Masahito ^a   Imose, Motoaki ^a   Naiki, Takafumi ^a   Kimura, Kiminori ^a   Hayashi, Hideki ^a   Shimizu, Masaru ^b   Ohnishi, Hiroo ^b   Tomita, Eiichi ^c   Sugihara, Jun'ichi ^c   Amano, Kazuo ^d   Sakai, Tsutomu ^d   Kojima, Takao ^e   Katsumura, Naoki ^f   Kondo, Yoshimasa ^g   Fujimoto, Masao ^h   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d Hashima City Hospital   (Japan)

^e ASAHI UNIVERSITY   (Japan)

^f Chuno Hospital   (Japan)

^g Ena Municipal Hospital   (Japan)

^h Department of Internal Medicine   (Japan)

Author keywords

Early virologic response; Hepatitis C virus; Interferon sensitivity determining region; Viral kinetics

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALGORITHM; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LONG TERM CARE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; REFERENCE VALUE; RNA ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

EID: 29144479385     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.08.010     Document Type: Article

References (32)

1. J.E. Layden T.J. Layden How can mathematics help us understand HCV? Gastroenterology 120 2001 1546-1549
2. N.P. Lam A.U. Neumann D.R. Gretch T.E. Wiley A.S. Perelson T.J. Layden Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 1997 226-231
3. S. Zeuzem J.M. Schmidt J.H. Lee B. Ruster W.K. Roth Effect of interferon-alpha on the dynamics oh hepatitis C virus turnover in vivo Hepatology 23 1996 366-371
4. A.U. Neumann N.P. Lam H. Dehari et al. Hepatotos C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy Science 282 1998 103-107
5. A.U. Neumann N.P. Lam H. Dehari et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus J Infect Dis 182 2000 28-35
6. F.C. Bekkering J.T. Brouwer S.W. Schalm A. Elewaut Hepatitis C viral kinetics Hepatology 26 1997 1691-1693
7. S. Zeuzem E. Herrmann J.H. Lee et al. Viral kinetics in patients with chronic hepatitis treated with atandard and peginterferon alpha-2a Gastroenterology 120 2001 1438-1447
8. F.C. Bekkering C. Stalgis J.G. McHutchison J.T. Brouwer A.S. Perelson Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model Hepatology 33 2001 419-423
9. E. Orito M. Mizokami K. Suzuki et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C J Med Virol 46 1995 109-115
10. S. Kakumu T. Aiyama A. Okumura K. Iwata T. Ishikawa K. Yoshioka Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C J Gastroen Hepatol 12 1997 468-472
11. Y. Asahina N. Izumi M. Uchihara et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta Hepatology 34 2001 377-384
12. G.L. Davis R. Esteban-Mur V. Rustgi et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N Engl J Med 339 1998 1493-1499
13. S. Iino E. Tomita H. Kumada et al. Impact of daily high-dose IFNα-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype I and high HCV RNA levels Hepatol Res 31 2005 88-94
14. J.G. McHutchison S.C. Gordon E.R. Schiff et al. Interferon alpha-2b monotherapy versus interferon alpha-2b plus ribavilin as initial treatment for chronic hepatitis C: Results of a U.S. multicenter randomized conrolled study N Engl J Med 339 1998 1485-1492
15. T. Poynard P. Marcellin S.S. Lee et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426-1432
16. V.J. Desmet M. Gerber J.H. Hoofnagle M. Manns P.J. Sceuer Classification od chronic hepatitis: Diagnosis, grading, and staging Hepatology 19 1994 1513-1520
17. H. Okamoto Y. Sugiyama S. Okada et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources J Gen Viol 73 1992 673-679
18. T. Ohno M. Mizokami R-R. Wu et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a J Clin Microbiol. 35 1997 201-207
19. N. Enomoto I. Sakuma Y. Asahina et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in NS5A region J Clin Invest 96 1995 224-230
20. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C Hepatology 36 2002 S3-S20
21. S. Iino E. Tomita H. Kumada et al. Prediction of treatment outcome with daily high-dose IFNa-2b plus rebavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: Relationship of baseline viral levels and viral dynamics during and after therapy Hepatol Res 30 2004 63-70
22. A.L. Ballesteros S. Franco D. Fuster et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: Indications for the investigation of new treatment approaches AIDS 18 2004 59-66
23. A. Magalini M. Puoti V. Putzolu et al. Decrease of HCV RNA after three days of daily interferon treatment is predictive of the virological response at one month J Clin Lab Anal 14 2000 120-124
24. T. Berg C. Sarrazin E. Herrmann et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy Hepatology 37 2003 600-609
25. A. Tsubota Y. Arase T. Someya et al. Early viral kinetics and treatment outcome in combination of high-dose interferon vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C of genotype 1b and high viral load J Med Virol 75 2005 27-34
26. G.L. Davis Monitoring of viral levels during therapy of hepatitis C Hepatology 36 2002 S145-S151
27. G.L. Davis J.B. Wong J.G. McHutchison M.P. Manns J. Harvey J. Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645-652
28. S. Nishiguchi T. Ueda T. Itoh et al. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy Hepatology 33 2001 241-247
29. N. Ibarrola J.A. Moreno-Monteagudo M. Saiz et al. Response to retreatment with interferon-alphs plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence Am J Gastroenterol 94 1999 2487-2495
30. J. Nousbaum S.J. Polyak S.C. Ray et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy J Virol 74 2000 9028-9038
31. G. Cappiello I. Abbate O. Lo lacono et al. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin Antivir Ther 8 2003 105-110
32. E. Ueda N. Enomoto N. Sakamoto et al. Changes of HCV quasispecies during combination therapy with interferon and ribavirin Hepatol Res 29 2004 89-96